Dentists, as trusted healthcare providers, have an opportunity to serve as a resource for evidence-based information, helping to educate colleagues and the public about COVID-19 vaccination. Answering questions, helping to allay concerns, and providing up-to-date guidance based on available data will enable individuals to make informed decisions regarding COVID-19 vaccination and bring us closer to putting an end to the current pandemic.

**Status of COVID-19 vaccines in the U.S.**

- Only a vaccine with Emergency Use Authorization (EUA) or approval from the U.S. Food and Drug Administration (FDA) can be administered in the U.S.
- The advisory committee to the FDA recommended EUA for the vaccine produced by Pfizer/BioNTech, and the FDA granted EUA on Dec. 11, 2020.
- A second vaccine, produced by Moderna, is before the advisory committee to the FDA on Dec. 17, 2020.
- The Pfizer/BioNTech COVID-19 vaccine was also granted EUA in United Kingdom (U.K.) and vaccine administration began there on December 8, 2020.
- On Dec. 9, 2020 the Pfizer/BioNTech COVID-19 vaccine was approved by Health Canada, the regulatory agency of Canada.

**Are Dentists Included in the First Wave of Vaccination?**

- Final authority rests with the individual states to prioritize populations to be offered the vaccine.
- Current [CDC guidance](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/phases.html) indicates that once a COVID-19 vaccine has EUA, during the initial phase of the COVID-19 vaccination program, the vaccine should be offered to both 1) healthcare personnel with potential for direct or indirect exposure to patient or infectious materials; and 2) residents of long-term care facilities. This is based, in part, on the National Academies of Science, Engineering and Medicine (NASEM) framework of a phased approach for equitable allocation of the vaccine, which prioritizes healthcare workers (including dentists and dental hygienists) and first responders in Phase 1a.

**Safety and Effectiveness of COVID-19 Vaccines**

- Data suggest that widespread use of the Pfizer/BioNTech and other vaccine(s) with similar safety and efficacy profiles have great potential to reduce the circulating levels of this virus.
- Data on the Pfizer/BioNTech COVID-19 vaccine far exceed the original FDA criterion of 30% efficacy in phase 3 clinical trials.
- Current guidance from CDC is that the second dose should be the same product as the first dose as per clinical trial protocol.
- Some details in the FDA analysis of the Pfizer/BioNTech COVID vaccine, indicate the following:
  - Vaccine efficacy after the second dose, against confirmed COVID-19 infection, was 95.0%.
  - Vaccine efficacy after the second dose, against serious COVID-19 disease, was nearly 100%. Mild-to-moderate adverse reactions to the vaccine were more frequent in study participants younger than 55...
years of age; otherwise. The safety profile was similar across age groups, genders, ethnic and racial groups as well as those with or without medical co-morbidities.

- Follow-up with participants in the phase 3 clinical trials noted that patients experienced the same sort of minor discomforts known to commonly occur following any sort of vaccination, such as injection-site reactions and some generalized malaise.
- Read the full details from the Pfizer/BioNTech FDA report.
- Monitoring where vaccines are being administered to populations is ongoing; some adverse reactions have been reported in individuals who have had previous serious allergic reactions to previous vaccines.

The ADA will continue to monitor developments related to COVID-19 vaccine approval and administration on behalf of the profession and public. Please visit ADA.org/virus for information for dental professionals and MouthHealthy.org for information for patients.

Disclaimer. These materials are intended to provide helpful information to dentists and dental team members. They are in no way a substitute for actual professional advice based upon your unique facts and circumstances. This content is not intended or offered, nor should it be taken, as legal or other professional advice. You should always consult with your own professional advisors (e.g. attorney, accountant, insurance carrier). To the extent ADA has included links to any third party web site(s), ADA intends no endorsement of their content and implies no affiliation with the organizations that provide their content. Further, ADA makes no representations or warranties about the information provided on those sites.